Monoclonal Antibody (F5) to Human Prostate Antigen

Abstract

Hybridoma culture F5 has been developed which secretes monoclonal antibody (McAb) directed to an epitope of a prostatic glycoprotein of Mr 34 kD (Prostate Antigen, PA). Tissue levels of PA have been evaluated using a competitive-binding enzyme-immunoassay based upon the inhibition of McAb binding activity to purified antigen. Results indicated the specific occurrence of high antigen concentrations in extracts prepared from prostatic tissues. The antigenicity of epitope F5 is resistant to tissue fixation and embedding protocols, and has been demonstrated upon immunoperoxidase staining procedures. Immunoperoxidase data strongly indicate that McAb F5 possesses a singular specificity towards prostatic epithelial cells. Other tissues, whether normal or cancerous, fail to express this determinant. Specimens examined included epithelial and nonepithelial tissues along with a panel of carcinomas and sarcomas. The antibody was able to detect tumor cells at extra-prostatic sites and represents a powerful probe for the detection and differential diagnosis of metastatic cancer of the prostate.

Heterogenous expression of cell-surface antigens in normal epithelia and their tumours, revealed by monoclonal antibodies

“…Some antigens are, however, clearly expressed in the cytoplasm of normal cells and show heterogeneous staining of tumours. These include a prostate antigen described by Papsidero et al (1983) and certain cytokeratin antigens (Gatter & Mason, 1982;Ramaekers et al, 1983) as discussed in more detail below.…”

Prostate-Specific Antigen and Early Detection of Prostate Cancer

“…It has been well recognized that the clinical applica tion of PSA was based upon the prostate spec ificity of the PSA molecule [3,15,16]. Pros tate tissue and cell-type specificity of PSA was well appreciated by 1981, as well documented in several papers of ours [3,[17][18][19][20].…”

“…This improved procedure along with PSA monoclonal antibody prepared by Dr. Papsidero in 1983 [15] greatly facilitated the trans fer of our PSA technology to biomedical in dustry, which subsequently has made PSA reagents readily available since 1986 (table 1). Consequently, basic research and clinical ap plication of PSA was extensively investigated, as noted from the exponential increase in the number of papers published on PSA (table 2), and has led to the widespread use of PSA in patient care today all around the world.…”

Epitope mapping of human prostate specific antigen and glandular kallikrein expressed in insect cells

“…5,23,24 The monoclonal antibodies H50, H68, H117, H164 and H179 were obtained from Abbott Laboratories (Abbott Park, Illinois), antibody F5 25 was from Dr Chu and antibodies 6, 10, 19, 25, 30, 36 and 66 were obtained as a kind donation from Dr Olle Nilsson (CanAG Diagnostics, Go È teborg, Sweden). Immunoreactivity and af®nity constants were determined using different two-site combinations of capture antibody and europium chelate-labelled antibody with time-resolved uorometry as described by Pettersson et al 23 The af®nity constants were measured according to the method of Scatchard.…”